Extended indication Extension of indication to include long-term prophylaxis (deletion of wording ‘short-term’ and currently listed conditions) of purpura fulminans and c
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Proteïne C
Domain Cardiovascular diseases
Reason of inclusion Indication extension IND
Main indication Antithrombotic medications
Extended indication Extension of indication to include long-term prophylaxis (deletion of wording ‘short-term’ and currently listed conditions) of purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein C deficiency.
Proprietary name Ceprotin
Manufacturer Takeda
Mechanism of action Unknown
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date April 2022
Expected Registration February 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

References medicijnkosten
Additional remarks De gemiddelde prijs per verpakking ex. btw is € 1.024. De behandelduur is nog niet bekend.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information